Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
Top Cited Papers
- 1 January 2008
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 47 (1), 97-104
- https://doi.org/10.1002/hep.21966
Abstract
This study prospectively evaluates the accuracy of contrast-enhanced ultrasound (CEUS) and dynamic magnetic resonance imaging (MRI) for the diagnosis of nodules 20 mm or smaller detected during ultrasound (US) surveillance. We included 89 patients with cirrhosis [median age, 65 years; male 53, hepatitis C virus 68, Child-Pugh A 80] without prior hepatocellular carcinoma (HCC) in whom US detected a small solitary nodule (mean diameter, 14 mm). Hepatic MRI, CEUS, and fine-needle biopsy (gold standard) (FNB) were performed at baseline. Non-HCC cases were followed (median 23 months) by CEUS/3 months and MRI/6 months. FNB was repeated up to 3 times and on detection of change in aspect/size. Intense arterial contrast uptake followed by washout in the delayed/venous phase was registered as conclusive for HCC. Final diagnoses were: HCC (n = 60), cholangiocarcinoma (n = 1), and benign lesions (regenerative/dysplastic nodule, hemangioma, focal nodular hyperplasia) (n = 28). Sex, cirrhosis cause, liver function, and alpha-fetoprotein (AFP) levels were similar between HCC and non-HCC groups. HCC patients were older and their nodules significantly larger ( P < 0.0001). First biopsy was positive in 42 of 60 HCC patients. Sensitivity, specificity, and positive and negative predictive values of conclusive profile were 61.7%, 96.6%, 97.4%, and 54.9%, for MRI, 51.7%, 93.1%, 93.9%, and 50.9%, for CEUS. Values for coincidental conclusive findings in both techniques were 33.3%, 100%, 100%, and 42%. Thus, diagnosis of HCC 20 mm or smaller can be established without a positive biopsy if both CEUS and MRI are conclusive. However, sensitivity of these noninvasive criteria is 33% and, as occurs with biopsy, absence of a conclusive pattern does not rule out malignancy. These results validate the American Association for the Study of Liver Disease (AASLD) guidelines. (Hepatology 2007.)Keywords
This publication has 27 references indexed in Scilit:
- Prevention of Hepatocellular CarcinomaSeminars in Liver Disease, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Hepatocellular carcinoma: Recent trends in JapanGastroenterology, 2004
- Hepatocellular carcinoma in cirrhosis: Incidence and risk factorsGastroenterology, 2004
- Primary liver cancer: Worldwide incidence and trendsGastroenterology, 2004
- Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complicationsGut, 2004
- Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance☆Gastroenterology, 2004
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and deathGut, 2000
- Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver DiseaseNew England Journal of Medicine, 1993